Sanofi Reports Growth as It Limits Drug Program
The company reported 14.44 billion euros in quarterly sales while narrowing the scope of its tolebrutinib development.
Updated on Oct. 30, 2026 in Biotech
Live Poll
Do you trust that large pharmaceutical companies prioritize patient health outcomes over corporate sales growth?
Sanofi reported third-quarter net sales of 14.44 billion euros, a 14.3% increase, even as the company winds down development of the drug tolebrutinib following regulatory setbacks. Tolebrutinib development is now limited to a restricted launch in Germany.
Why it matters
Sanofi is reallocating research and development resources toward commercial medicines in core disease areas to address investor concerns. This shift follows safety questions and a 2025 FDA rejection for tolebrutinib.
Sanofi recorded 1.8 billion euros in R&D expenses for the third quarter. The company saw new pharmaceutical product revenue grow 41% to 1.4 billion euros, while its Dupixent therapy reached 5.7 billion euros, a 35% growth rate.
The players
Sanofi
A French multinational pharmaceutical company focused on immunology, vaccines, and late-stage commercial medicine development.
The details
Sanofi uses a risk management program to monitor tolebrutinib, which is now restricted to a limited launch in Germany. The drugmaker pivots its R&D strategy when assets fail to meet strict safety and regulatory requirements, such as the complete response letter—a notice that the FDA cannot approve an application in its current form—received in late 2025. This strategy emphasizes late-stage development over high-risk experimental programs.
Timeline
2020: Sanofi acquires the company Principia.
Late 2025: The FDA issues a complete response letter for tolebrutinib.
Summer 2026: Tolebrutinib receives European regulatory clearance.
October 1, 2026: Tolebrutinib launches in Germany.
Third quarter 2026: The financial reporting period for Sanofi.
The Tech Race
Sanofi is realigning its pipeline after the 2025 FDA complete response letter for tolebrutinib forced a departure from its original clinical goals. The company is now prioritizing established assets like Dupixent, for which it has set a peak sales target of 25 billion euros.
Tolebrutinib is currently available only in Germany under a strict risk management program. Patients and clinicians globally should note that development of the drug has been otherwise wound down due to safety and regulatory concerns.
The takeaway
Sanofi is doubling down on commercial performance while trimming its experimental portfolio to stabilize its R&D trajectory. Investors should monitor the full-year 2026 sales growth, which the company currently forecasts at a low-teen percentage.
Further reading
Explore more developments in the Biotech sector.
Live Poll
Do you trust that large pharmaceutical companies prioritize patient health outcomes over corporate sales growth?
